Christina Elisabeth Herder
Directeur Général chez IDOGEN AB (PUBL)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Magnus Essand | M | 60 | 10 ans | |
Eva Agneta Edberg | F | 68 | 4 ans | |
Di Yu | M | 39 | 10 ans | |
Hans Peter Bøhn | M | 69 | 9 ans | |
Sharon Longhurst | M | 55 | 4 ans | |
Margareth Jorvid | F | 63 | 4 ans | |
Ellen Donnelly | M | 50 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 8 ans |
Rolf Ingvar Lenart | M | 68 | 8 ans | |
Jan Gustaf Zetterberg | M | 73 | 4 ans | |
Jamal El-Mosleh | M | 43 | 10 ans | |
Hilde Furberg | F | 65 | 5 ans | |
Lars Kåre Viksmoen | M | 75 | 8 ans | |
Maria Sofia Ekelund | F | 54 | - | |
Dennis Bang Henriksen | M | 62 | 9 ans | |
Han Jing Xie | M | 54 | 2 ans | |
Rory Graham | M | - | 2 ans | |
Anna Koptina Gültekin | M | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Leif-Göran Salford | M | 83 | 14 ans | |
Karin Hoogendoorn | M | 54 | - | |
Anders Eric Karlsson | M | 59 | 3 ans | |
Andrew Hughes | M | - | 5 ans | |
Neil Thomas | M | - | 9 ans | |
Niklas Wallett | M | 48 | - | |
Joakim Söderström | M | 40 | - | |
Terese Hylander | M | 39 | 3 ans | |
Vicki Venizelos | F | - | - | |
Christina Brattström | F | - | 2 ans | |
Amir Snapir | M | - | 2 ans | |
Ludovic Robin | M | - | 2 ans | |
Lena Jendeberg | M | 60 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | - |
Hans Olivecrona | M | 66 | 3 ans | |
Johan Georg Harmenberg | M | 70 |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | - |
Gael L'Hévéder | M | 56 | 6 ans | |
Åsa Schiött | M | - | 2 ans | |
Lennart Svensson | M | 63 | 1 ans | |
Vendela Parrow | M | - |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | - |
Kjetil Taskén | M | 59 | 10 ans | |
Hilde Hermansen Steineger | M | 58 | 5 ans | |
Per Walday | M | 64 | 14 ans | |
Mikael Oerum | M | - | 3 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 29 | 72,50% |
Norvège | 11 | 27,50% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Christina Elisabeth Herder
- Réseau Personnel